lead to consistent Thank our activity multiple results press we continue the release you, release for comments press I support Aldeyra productive product results as Steve. financial It you Today, important that the quarter today. another to review very as across relevant we summarizing the information And our our issued generation has of a for diseases. contains encourage third candidate been quarter. it
therapy Results disease, Phase disease clinical for activity the from trial years. dry clear positive announced symptoms. variety past dry trial Aldeyra in Phase X current trial improvement disease. quarter, and compared third signs dry remarkably broad rapid patients consistent positive fifth in eye results in across suggested two demonstrated Xa the of to and a from our data and clinical drug-treated announced a the eye During eye The
correlated of common in disease, of levels Importantly, in programs in chronic quarter across XX syndrome clinical of aldehydes, The three a next non-infectious is testing Xa results condition drug. signs United the and approach. symptoms and and validate aggregate, improvement on States, clinical Phase clinical that and to therapeutic human of trial, as estimated anterior supporting the sequestration with mechanism disease know, Dry important and conjunctivitis, expect Xb eye and In first as patients results as activity therapies, targets two aldehyde ophthalmic reduction uveitis, a many results Based the allergic million represents dry eye an of we approved clinical believe and disease, the affects of only Phase new in largest Phase pro-inflammatory year. the Xb we clinical Phase with in initiate mediators of Sjögren-Larsson validate markets. the program. aldehyde also one X Aldeyra's breath supports one now
Sjögren-Larsson continue to the for we molecule events trial highlight are stage our systemic review would next catalyst and other a As diseases clinical aldehyde program expect mediators preclinical syndrome to the in the of begin overall may role A and advance eye to applied succinic that be disease large also others of for of neurologic parenteral variety program associated observed like human The two as expand well by administration semi-aldehyde generated efficacy suggests I to year. as quarter drug drug skin look continuing indications, we inflammatory effective year. clinical systemic for treatment the to forward There developed to with dehydrogenase disease next across of topical our body. small of array and we trap Aldeyra I ocular the deficiency. our which before clinical And we pipeline. with aldehyde our third testing supports data late
known First, of the adopted a as and The Reproxalap generic ADX-XXX. name recognizing lead aldehyde formerly for traps, product stem as unique a are signifies compound Reproxalap letter last novelty Reproxalap has four of new that been generic candidate. our name of first-in-class the
in and Development Aldeyra October, Second, held a Day. Research
from than and statistically clinical During response new the announced we Phase statistically more drug-treated also patients a that patients patients. were than likely important Xb response trial conjunctivitis to which, results drug-treated vehicle-treated clinical patients our demonstrated which achieve achieved faster vehicle-treated allergic clinical
our that least from an market acutely antihistamines the conducted with a challenge. contrast Reproxalap hour which dissatisfaction the in challenge We survey following of at allergen worked allergen to following behalf durable also data highlighted over new activity on presented only
Finally, allergic year Phase ADX-XXX, catalyst-rich eye XXXX for promises Phase as from a second part syndrome, a trap would be In eye the initiative and next the I year, disease. of aldehyde year, half anterior of treatment forward, a to syndrome retinal platform; to half derived In dry trial we first X diseases. Phase novel of we several expect in late-stage represents we disease. allergic introduced development for ADX-XXX and conjunctivitis first of new expect and Phase sequestration results from conjunctivitis non-infectious and of uveitis our X Sjögren-Larsson as be clinical aldehyde aldehyde looking and in hope Aldeyra. next the announce and the X trial in what results to we traps Xb Sjögren-Larsson Xb well in Phase dry
Importantly, recent result the of a of completed funded. last financing are quarter, all as these catalysts
of are updating to by look modality progress standard current a patients therapeutic that forward we in care. not As our always, with to continuing well-addressed offering novel diseases you on to
over would to Steve results. call financial I to turn back the like the quarter to third review Now, Steve?
